A Systematic Review of Regulatory requirements of Biosimilar Products: WHO, India, European Union and USFDA
Bibliographic record
Abstract
A biosimilar is a copy of an approved original biologic drug. Call for biosimilars is triggered by the expiration of the data protection on the original biologic medicine. A similar biologic biopharmaceutical product has been approved by the European Medicines Agency (EMA) because of its similarity in quality, safety, and efficacy to an innovator biologic product. Many nations, including Canada, Japan, the United States, India, and Korea, have released their own standards for evaluating follow-on biologics, based on WHO and EMA guidelines. When it comes to licensing biosimilar products/entities, this page discusses widely accepted criteria, with the goal of guaranteeing quality, safety and efficacy after full licensing dossier submission and license approval. Clinical and non-clinical data obtained with a previously licensed similar biologic medicinal product will be used in part to evaluate the degree of similarity between biosimilar and innovator biologic products for the licensing process. National regulatory frameworks can be built on these guidelines to license the products in question. It is the purpose of this article to discuss the numerous regulatory requirements for biosimilar clearance, including the WHO and several areas, such as India and the EU, as well as the US.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.008 | 0.022 |
| Meta-epidemiology (narrow) | 0.001 | 0.001 |
| Meta-epidemiology (broad) | 0.004 | 0.003 |
| Bibliometrics | 0.008 | 0.011 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.002 | 0.002 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.002 | 0.001 |
| Insufficient payload (model declined to judge) | 0.005 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".